What is the preferred drug for the treatment of ventricular tachycardia (VT)?

The preferred drug for the treatment of ventricular tachycardia (VT) in pediatric patients, particularly in emergency scenarios, is amiodarone. Amiodarone has shown efficacy in stabilizing cardiac rhythm during VT and is often used due to its broad spectrum of activity against both atrial and ventricular arrhythmias. Its ability to prolong the action potential and refractory period in myocardial tissue makes it particularly useful in managing VT, especially when the arrhythmia is symptomatic or when immediate cardioversion is not feasible.

Lidocaine, while historically used for this purpose, is not the first-line choice in pediatric patients. Its effectiveness can be limited, and current guidelines have moved toward recommending amiodarone due to its better safety profile and effectiveness in a range of tachyarrhythmias. Procainamide can also be an option for ventricular tachycardia, but it is generally reserved for specific conditions and requires monitoring for potential side effects. Flecainide, on the other hand, is primarily used for stable patients and is not typically employed in acute emergency settings for VT.

In conclusion, amiodarone is recognized as the preferred drug for treating ventricular tachycardia due to its efficacy and safety in the pediatric population.